EDGC announced that its affiliate, EDGC Healthcare has signed a contract worth of 30,000 doses with SYNLAB on behalf of SolGent to export COVID-19 diagnostic reagents to Europe on March 19.

SolGent’s Diagnostic reagents have passed the laboratory test conducted by SYNLAB and it will gradually increase the supply volume starting next week.

SYNLAB is a leading provider of laboratory diagnostic services based in Germany with annual sales of about 1.9 billion euros (about 2.6 trillion won) as of 2017 around Europe. The laboratory currently operates a total of 42 branches in 34 European countries, Middle East and South America, provides more than 500 million testing services annually to medical institutions including general hospitals and small check-up centers.

“We are receiving a number of contract inquiries from European countries after acquring the European Certification (CE) for COVID-19 diagnosis reagents.” said Lee Myung-hee, CEO of EDGC Healthcare. “We will do our best to ensure smooth supply of the diagnostic reagents through EDGC's global network.”

On the other hand, in order for medicines to be exported, they must first go through an approval process, such as obtaining export permission from the Ministry of Food and Drug Safety, and then obtain final approval in accordance with the regulations of the respective export licensing authorities prior to the sales in the relevant country. SolGent's COVID-19 diagnostic reagents are approved by both Ministry of Food and Drug Safety and European Certification, enabling export contracts and supply to European countries. SolGent is the only company that produces COVID-19 diagnostic reagents with localized raw materials among the four companies that have been approved for emergency use.  

[DiaPlexQ™ Novel Coronavirus (2019-nCoV) Detection Kit]